Heparin cofactor II-thrombin complex in MPS I: A biomarker of MPS disease

Molecular Genetics and Metabolism

Volumn 88, Issue 3, 2006, Pages 235-243

  Randall, Derrick R ^a   Sinclair, Graham B ^b   Colobong, Karen E ^a   Hetty, Elly ^a   Clarke, Lorne A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarker; Dermatan sulphate; Heparan sulphate; Heparin cofactor II; Iduronidase; iTRAQ; Mucopolysaccharidosis; Serine protease inhibitor; Serpin

Indexed keywords

BIOLOGICAL MARKER; HEPARIN COFACTOR II; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN;

ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; HUMAN; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS;

ADULT; ANIMALS; BIOLOGICAL MARKERS; CHILD; FEMALE; HEPARIN COFACTOR II; HUMANS; INFANT; MALE; MICE; MUCOPOLYSACCHARIDOSIS I; PROTEIN BINDING; PROTEOME; THROMBIN;

MURINAE;

EID: 33745484772     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.01.005     Document Type: Article

References (39)

1. Neufeld E.F., and Muenzer J. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. Eighth ed. (2001), McGraw-Hill, New York 3421-3452
2. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., and Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Pediatr. 144 (2004) 581-588
3. Beesley C.E., Meaney C.A., Greenland G., Adams V., Vellodi A., Young E.P., and Winchester B.G. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum. Genet. 109 (2001) 503-511
4. Terlato N.J., and Cox G.F. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet. Med. 5 (2003) 286-294
5. Quero C., Colome N., Prieto M.R., Carrascal M., Posada M., Gelpi E., and Abian J. Determination of protein markers in human serum: analysis of protein expression in toxic oil syndrome studies. Proteomics 4 (2004) 303-315
6. Avasarala J.R., Wall M.R., and Wolfe G.M. A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis: detection of three biomarkers. J. Mol. Neurosci. 25 (2005) 119-125
7. Sihlbom C., Davidsson P., and Nilsson C.L. Prefractionation of cerebrospinal fluid to enhance glycoprotein concentration prior to structural determination with FT-ICR mass spectrometry. J. Proteome Res. 4 6 (2005) 2294-2301
8. TM Reagents: Amine-specific Labeling Reagents for Multiplexed Relative and Absolute Protein Quantification, Applied Biosystem, Foster City, 2004, .
9. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., Khainovski N., Pillai S., Dey S., Daniels S., Purkayastha S., Juhasz P., Martin S., Bartlet-Jones M., He F., Jacobson A., and Pappin D.J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3 (2004) 1154-1169
10. Hardt M., Witkowska H.E., Webb S., Thomas L.R., Dixon S.E., Hall S.C., and Fisher S.J. Assessing the effects of diurnal variation on the composition of human parotid saliva: quantitative analysis of native peptides using iTRAQ reagents. Anal. Chem. 77 (2005) 4947-4954
11. DeSouza L., Diehl G., Rodrigues M.J., Guo J., Romaschin A.D., Colgan T.J., and Siu K.W. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 4 (2005) 377-386
12. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., Toone J., and Jirik F.R. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum. Mol. Genet. 6 (1997) 503-511
13. Pelzer H., Schwarz A., and Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb. Haemost. 59 (1988) 101-106
14. Hollak C.E., van Weely S., van Oerts M.H., and Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93 (1994) 1288-1292
15. Tollefsen D.M., Majerus D.W., and Blank M.K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257 (1982) 2162-2169
16. Pike R.N., Buckle A.M., le Bonniec B.F., and Church F.C. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J. 272 (2005) 4842-4851
17. Gettins P.G. Serpin structure, mechanism, and function. Chem. Rev. 102 (2002) 4751-4804
18. Byers S., Rozaklis T., Brumfield L.K., Ranieri E., and Hopwood J.J. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol. Genet. Metab. 65 (1998) 282-290
19. Gallegos-Arreola M.P., Machorro-Lazo M.V., Flores-Martinez S.E., Zuniga-Gonzalez G.M., Figuera L.E., Gonzalez-Noriega A., and Sanchez-Corona J. Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch. Med. Res. 31 (2000) 505-510
20. Mabe P., Valiente A., Soto V., Cornejo V., and Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin. Chim. Acta 345 (2004) 135-140
21. Mahalingam K., Janani S., Priya S., Elango E.M., and Sundari R.M. Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives. Indian J. Pediatr. 71 (2004) 29-32
22. Tollefsen D.M. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 4455-4471
23. Huntington J.A. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J. Thromb. Haemost. 1 (2003) 1535-1549
24. Tollefsen D.M., Pestka C.A., and Monafo W.J. Activation of heparin cofactor II by dermatan sulphate. J. Biol. Chem. 10 (1983) 6713-6716
25. He L., Vicente C.P., Westrick R.J., Eitzman D.T., and Tollefsen D.M. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J. Clin. Invest. 109 (2002) 213-219
26. Ishiguro K., Kojima T., Kadomatsu K., Nakayama Y., Takagi A., Suzuki M., Takeda N., Ito M., Yamamoto K., Matsushita T., Kusugami K., Muramatsu T., and Saito H. Complete antithrombin deficiency in mice results in embryonic lethality. J. Clin. Invest. 106 (2000) 873-878
27. Zammit A., and Dawes J. Fibrinogen inhibits the heparin cofactor II-mediated antithrombin activity of dermatan sulphate. Blood 85 (1995) 720-726
28. Simonaro C.M., Haskins M.E., and Schuchman E.H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab. Invest. 81 (2001) 1319-1328
29. Walkley S.U., Thrall M.A., Haskins M.E., Mitchell T.W., Wenger D.A., Brown D.E., Dial S., and Seim H. Abnormal neuronal metabolism and storage in mucopolysaccharidosis type VI (Maroteaux-Lamy) disease. Neuropathol. Appl. Neurobiol. 31 (2005) 536-544
30. Owen C.A., and Campbell E.J. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J. Immunol. 160 (1998) 1436-1443
31. Bank U., Kupper B., Reinhold D., Hoffmann T., and Ansorge S. Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation. FEBS Lett. 461 (1999) 235-240
32. Shamamian P., Schwartz J.D., Pocock B.J., Monea S., Whiting D., Marcus S.G., and Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J. Cell. Physiol. 189 (2001) 197-206
33. Parker K.A., and Tollefsen D.M. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J. Biol. Chem. 260 (1985) 3501-3505
34. Bergman B.L., Scott R.W., Bajpai A., Watts S., and Baker J.B. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc. Natl. Acad. Sci. USA 83 (1986) 996-1000
35. Buchholz M., Biebl A., Neebetae A., Wagner M., Iwamura T., Leder G., Adler G., and Gress T.M. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 63 (2003) 4945-4951
36. Meyer C., Notari L., and Becerra S.P. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J. Biol. Chem. 277 (2002) 45400-45407
37. J.L Ashworth, S. Biswas, E. Wraith, and I.C. Lloyd, The ocular features of the mucopolysaccharidoses, Eye advance online publication, 20 May 2005 (doi:10.1038/sj.eye.6701921).
38. Pannell R., Johnson D., and Travis J. Isolation and properties of human plasma alpha-1-proteinase inhibitor. Biochemistry 13 (1974) 5439-5445
39. Faller B., Frommherz K., and Bieth J.G. Heparin interferes with the inhibition of neutrophil elastase by its physiological inhibitors. J. Biol. Chem. 373 (1992) 503-508